ASML heads into July 15 while Lam Research keeps outrunning it

ASML ASML is not arriving at earnings in a vacuum. The semiconductor equipment group has been living off the same broad AI spending cycle, and the latest industry billings data still points in the same direction. Global semiconductor equipment billings rose 14% year over year to a record $36.55 billion in the first quarter of 2026, led by leading-edge logic, DRAM, and advanced packaging. The backdrop is clear. The stock-specific question is whether ASML, the monopoly supplier of extreme ultraviolet lithography systems, can keep translating that demand into numbers that justify the premium the market has already handed it.

Lam Research is the useful foil because it shows what happens when the market decides the equipment cycle is still early enough to pay up for exposure. Lam shares are up more than 100% year to date through mid-July and hit record highs in late June alongside Applied Materials. ASML has also climbed hard this year, but the pace is different. That gap matters. When two names sit in the same capital-spending lane and one is running ahead of the other, you are not just comparing businesses. You are comparing how much of the cycle each stock has already priced in.

July 15 is the test, not the chart

ASML’s second-quarter 2026 earnings release lands on July 15, and the company has already given the market a frame to work with. It is guiding for net sales between €8.4 billion and €9.0 billion, with gross margin at 51% to 52%. That is a tight enough range to matter. If the company lands near the top end, the market will read it as confirmation that leading-edge demand is still doing the heavy lifting. If it comes in soft, the stock will not get the benefit of the doubt for long, because the shares have already had a strong run.

Lam Research does not have the same singularity in its product mix, but that is part of why it has been easier for the market to trade. ASML’s exposure is narrower and more strategic. Its high-NA EUV tools sit at the center of the most advanced node transitions, which makes the company essential and also makes the stock more sensitive to any hint that customers are pacing orders or stretching delivery schedules. Lam can benefit from the same capex wave through a broader set of process steps. ASML has to prove that the most expensive part of the chain still deserves the same enthusiasm.

The market has already done some of that work for it. ASML.AS closed at €1,602.80 on July 9 after trading as high as €1,625.20 that session. The U.S.-listed ADR was around $1,797 to $1,804 in the same period. Those are not distressed prints. They are the kind of levels that force you to ask whether the next catalyst is already in the price. Lam Research, by contrast, has been rewarded for momentum. That is the comparison that frames ASML now.

Buybacks are doing the talking while insiders stay quiet

ASML continued share repurchases from June 29 through July 3 under its ongoing program, averaging roughly €15.9 million per day. That is not a headline-grabbing number in the way an insider buy would be, but it is still a clear signal of how management is choosing to allocate capital at current levels. The company is not standing still and waiting for the market to decide what the stock should be worth. It is taking shares out of circulation while the business heads into a key earnings date.

The insider record is quieter than the buyback tape. No insider transactions have been reported in the most recent seven days, and the latest activity in the record occurred in February 2026. That leaves you with a different kind of read than the one you get from a cluster of fresh buys. There is no new personal trade to lean on here, just a company that is still repurchasing stock and a management team that has not added fresh insider color in the last week.

That contrast matters against Lam Research because Lam has been the more aggressive stock in the public market, not because its insiders are doing something more dramatic. The market has done the work for Lam. ASML’s own capital return program is the more visible action right now. If you want a clean read, that is the one on the page.

How to read the historical cohort data

Because there are no fresh insider transactions in the last seven days, the historical cohort read has to do more of the explanatory work than usual. It is still only a comparison point. It does not tell you what ASML will do after July 15. It tells you what similar filings have looked like over the next 90 days in the past, and that is a narrower, humbler thing.

The useful part is the discipline it imposes. If the stock is already up strongly, if the company is still buying back shares, and if the insider record is stale, then you are not looking at a fresh conviction cluster. You are looking at a business that has to earn the next leg the old-fashioned way, through the print and the guide. Lam Research does not need the same proof in the same way because the market has already been willing to pay for its momentum. ASML has to defend a more demanding valuation with a more concentrated product story.

That is where the historical cohort data belongs in the comparison. It is not a verdict on ASML. It is a reminder that the absence of fresh insider activity leaves the earnings release as the main event, while the cohort read sits in the background as a reference for how similar filings have behaved after the fact.

ASML’s monopoly is the point, and Lam’s breadth is the trade-off

ASML’s edge is simple to state and hard to replicate. It is the primary supplier of EUV lithography systems, and that position gives it direct exposure to the most advanced chip production. In a cycle driven by AI infrastructure buildouts, that is a powerful place to be. The company does not need the whole semiconductor market to be hot. It needs the leading edge to keep spending.

Lam Research is a different kind of beneficiary. Its business sits in overlapping wafer fabrication equipment segments, and that breadth has helped the stock participate in the same AI capex wave. The market has rewarded that breadth with a faster share-price move. ASML’s narrower exposure is the reason it can be more strategically important and more difficult to trade. When the market is paying up for AI infrastructure, breadth can be a virtue. When the market starts asking which names still have room to rerate, monopoly exposure can become the cleaner story, but only if the next quarter confirms it.

The comparison is not about which company is better. It is about which one has already been more fully recognized by the market. Lam Research has been the more explosive stock. ASML has been the more singular business. Those are not the same thing, and the gap between them is where the trade lives.

The valuation question is really a timing question

European tech has not been immune to valuation anxiety, even with the AI spending cycle still intact. Reuters noted that broader European indices have recently seen tech-led pullbacks as investors reassess stretched names. ASML sits right in that cross-current. It has the kind of business quality that can justify a premium, but it also has the kind of premium that gets tested every time the market rotates away from growth or asks for proof that the cycle is still extending.

Lam Research has been able to outrun that concern because the market has treated it as a direct beneficiary of the same spending wave, with a stock chart that has already done a lot of the talking. ASML’s chart has been strong too, but the higher the stock goes, the more the July 15 print matters. A company guiding to €8.4 billion to €9.0 billion in sales and 51% to 52% gross margin does not need a miracle. It does need to avoid giving the market a reason to question the pace of demand.

That is the practical difference between the two names. Lam can keep riding the theme as long as the capex story stays hot. ASML has to keep proving that the most advanced part of the chain is still the part customers cannot defer. The market will not pay forever for the idea that AI spending is broad. It pays when the numbers keep coming.

What to watch after July 15, and why Lam still matters in the background

The next concrete data point is the July 15 earnings release, followed by whatever ASML says about full-year 2026 sales, which had previously been framed in the €36 billion to €40 billion range. That is the number that will tell you whether the company still sees enough demand to support the current valuation and the current mood around the stock. The buyback pace from late June into early July is useful, but it is not the main event. The main event is whether the company can keep the guide intact or improve it.

Lam Research remains the right comparison because it shows the market’s current appetite for equipment exposure. If Lam keeps making new highs while ASML merely holds its ground, that tells you something about relative enthusiasm, not about the quality of the businesses. If ASML catches up after earnings, that tells you the market still wants the monopoly story when the numbers back it up. Either way, the comparison is live.

For now, the setup is straightforward. ASML has a strong business, a still-supportive sector backdrop, active buybacks, and no fresh insider transactions in the last seven days. Lam Research has the hotter stock. July 15 will decide whether ASML deserves to close that gap or whether the market keeps paying more for the broader, faster-moving equipment name.

This is not investment advice.